Baird Maintains Outperform on Calidi Biotherapeutics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains an Outperform rating on Calidi Biotherapeutics (AMEX:CLDI) but lowers the price target from $4.5 to $2.
May 15, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst Joel Beatty maintains an Outperform rating on Calidi Biotherapeutics but lowers the price target from $4.5 to $2.
The lowered price target from $4.5 to $2 suggests a more cautious outlook on the stock's potential, which could lead to a short-term negative impact on the stock price despite the maintained Outperform rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100